WallStSmart

Abbott Laboratories (ABT)vsSeaboard Corporation (SEB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 359% more annual revenue ($45.13B vs $9.83B). ABT leads profitability with a 13.9% profit margin vs 5.9%. SEB appears more attractively valued with a PEG of 0.65. SEB earns a higher WallStSmart Score of 65/100 (B-).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

SEB

Strong Buy

65

out of 100

Grade: B-

Growth: 5.3Profit: 4.5Value: 9.3Quality: 8.0
Piotroski: 5/9Altman Z: 3.59
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+0.6%)

Margin of Safety

+0.6%

Fair Value

$87.53

Current Price

$84.32

$3.21 discount

UndervaluedFair: $87.53Overvalued
SEBUndervalued (+49.9%)

Margin of Safety

+49.9%

Fair Value

$11112.70

Current Price

$4540.14

$6572.56 discount

UndervaluedFair: $11112.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

SEB5 strengths · Avg: 9.6/10
P/E RatioValuation
7.5x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

EPS GrowthGrowth
277.0%10/10

Earnings expanding 277.0% YoY

Altman Z-ScoreHealth
3.5910/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.658/10

Growing faster than its price suggests

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

SEB4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.6%4/10

3.6% revenue growth

Profit MarginProfitability
5.9%3/10

5.9% margin — thin

Operating MarginProfitability
4.0%3/10

Operating margin of 4.0%

Free Cash FlowQuality
$-150.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : SEB

The strongest argument for SEB centers on P/E Ratio, Price/Book, EPS Growth. PEG of 0.65 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : SEB

The primary concerns for SEB are Revenue Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

ABT carries more volatility with a beta of 0.65 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SEB scores higher overall (65/100 vs 56/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Seaboard Corporation

INDUSTRIALS · CONGLOMERATES · USA

Seaboard Corporation is a global agribusiness and transportation company. The company is headquartered in Merriam, Kansas.

Visit Website →

Want to dig deeper into these stocks?